Phase 1 Autism Spectrum Disorder Trial, Recruiting NCT06030752 Sponsor: The Second Hospital of Nanjing Medical University Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Phase 1 Autism Spectrum Disorder Trial, Recruiting

NCT06030752
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children and adolescents who have been formally diagnosed with ADHD, or both ADHD and autism (ASD), based on standard diagnostic guidelines (DSM-5).
  • People aged 3 to 17 years old.
  • People who have been on a stable treatment plan for at least 1 month before the trial's gut microbiome therapy begins.

Who may not be able to join:

  • People whose parent or legal guardian is unable to understand the study questionnaires or give formal consent on their behalf.
  • People who have been diagnosed with a single-gene disorder, a major brain malformation, or certain bowel conditions such as ulcerative colitis, Crohn's disease, or eosinophilic esophagitis.
  • People who have serious health conditions affecting the heart, lungs, liver, or kidneys, a severe infection, or cancer.
  • People who have another life-threatening condition that requires urgent medical treatment.
  • People who are unable to safely undergo a colonoscopy procedure or the anaesthesia used during it.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Faming Zhang, PhD, The Second Hospital of Nanjing Medical University

Phone: 086-25-58509883

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
The Second Hospital of Nanjing Medical University
Registry
ClinicalTrials.gov
Start date
20 September 2023
Est. completion
4 April 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Changes in the Autism Behavior Checklist (ABC) in ASD children; Change in Autism Treatment Evaluation Checklist (ATEC) in ASD children

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov